NEW YORK, Sept. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017 http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania

between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in
France
in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with 49% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while C anada
is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (
Ireland
), GE Healthcare (U.K.), IBA Group (
Belgium
), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (
Canada
), and Siemens Healthcare (PETNET) (
Germany
).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 90% to the global revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of

isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America , Europe , Asia , and Rest of the World) to provide in-depth information on the global scenario.

Global Radiopharmaceuticals Market

DiagnosticSPECTTc-99mTl-201Ga-67I-123OthersPETF-18Rb-82OthersTherapyBeta emittersI-131Sm-153Re-186

Y-90Lu-177OthersAlpha emittersBrachytherapyCs-131I-125Pd-103Ir-192Others

Global Enriched Stable Isotopes Market

DeuteriumOxygen-18Carbon-13Nitrogen-15Others

Radiopharmaceutical and Stable Isotope Markets, By Geography

North AmericaEurope, including RussiaAsiaRoW (Africa, LATAM, Middle-East, Pacific countries)

1 INTRODUCTION 28

1.1 KEY TAKE-AWAYS 281.2 REPORT DESCRIPTION 281.3 MARKETS COVERED 301.4

LIST OF TABLES

LIST OF FIGURES

To order this report: **Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017** **http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging**

_____Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKS http://www.reportlinker.com